Fintel reports that on February 2, 2026, Guggenheim initiated coverage of Cullinan Therapeutics (NasdaqGS:CGEM) with a Buy ...

Cash-rich Cullinan Therapeutics stock: zipalertinib NDA in Q1 2026 plus CLN-978 and CLN-049 AML catalysts. Read here for more analysis.

The General Confederation of Moroccan Enterprises (CGEM), a premier network of entrepreneurs, is urging the creation of localised and complementary value chains across Africa to accelerate ...

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring ...

Cullinan Therapeutics Inc. (NASDAQ:CGEM) is one of the stocks that will double in 2026. On December 10, Clear Street raised the firm’s price target on Cullinan Therapeutics to $33 from $22 with a Buy ...

Fintel reports that on November 24, 2025, BTIG maintained coverage of Cullinan Therapeutics (NasdaqGS:CGEM) with a Buy recommendation. Analyst Price Forecast Suggests 177.65% Upside As of November 17, ...

The latest price target for Cullinan Therapeutics (NASDAQ:CGEM) was reported by Wedbush on December 9, 2025. The analyst firm set a price target for $34.00 expecting CGEM to rise to within 12 months ...

Lynx1 Capital Management LP, a ten percent owner of Cullinan Therapeutics, Inc. (NASDAQ:CGEM), reported purchasing shares of the company’s common stock in a series of transactions totaling $2,103,912.

Lynx1 Capital Management LP, along with Weston Nichols, reported purchasing shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a $437.74 million market cap biotech company, in three separate ...

Lynx1 Capital Management LP, along with Weston Nichols, reported purchasing shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a $437.74 million market cap biotech company, in three separate ...